CLINICAL TRIALS PROFILE FOR DORNASE ALFA
✉ Email this page to a colleague
All Clinical Trials for dornase alfa
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00204685 ↗ | Time of Ventilation and Lung Function of Ventilated Patients Under Therapy With Dornase Alfa | Unknown status | Joachim Riethmueller, Dr. med. | Phase 2/Phase 3 | 2003-08-01 | The purpose of this study is to determine whether Inhalation of Recombinant Human Deoxyribonuclease Shortens Ventilation Time in Mechanically Ventilated Adults |
| NCT00204685 ↗ | Time of Ventilation and Lung Function of Ventilated Patients Under Therapy With Dornase Alfa | Unknown status | University Hospital Tuebingen | Phase 2/Phase 3 | 2003-08-01 | The purpose of this study is to determine whether Inhalation of Recombinant Human Deoxyribonuclease Shortens Ventilation Time in Mechanically Ventilated Adults |
| NCT00265434 ↗ | Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis | Completed | Dr. Gerlind Schneider | Phase 3 | 2005-12-01 | Rhinosinusitis disorders are often associated with Cystic Fibrosis. They can restrict quality of life enormously and give cause to repeated ENT surgery. The basic defect in CF is a dysfunction of Chloride channels in exocrine glands, leading to retention of secretions and consecutive chronic inflammation with bacterial superinfections. The prospective placebo controlled cross-over study aims at the evaluation of the efficacy of a nasally inhalation of Pulmozyme with respect to mucus retention and resulting inflammation. |
| NCT00265434 ↗ | Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis | Completed | PD Dr. Assen Koitschev, Tübingen | Phase 3 | 2005-12-01 | Rhinosinusitis disorders are often associated with Cystic Fibrosis. They can restrict quality of life enormously and give cause to repeated ENT surgery. The basic defect in CF is a dysfunction of Chloride channels in exocrine glands, leading to retention of secretions and consecutive chronic inflammation with bacterial superinfections. The prospective placebo controlled cross-over study aims at the evaluation of the efficacy of a nasally inhalation of Pulmozyme with respect to mucus retention and resulting inflammation. |
| NCT00265434 ↗ | Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis | Completed | PD Dr. Joachim Riethmöller, Tübingen | Phase 3 | 2005-12-01 | Rhinosinusitis disorders are often associated with Cystic Fibrosis. They can restrict quality of life enormously and give cause to repeated ENT surgery. The basic defect in CF is a dysfunction of Chloride channels in exocrine glands, leading to retention of secretions and consecutive chronic inflammation with bacterial superinfections. The prospective placebo controlled cross-over study aims at the evaluation of the efficacy of a nasally inhalation of Pulmozyme with respect to mucus retention and resulting inflammation. |
| NCT00265434 ↗ | Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis | Completed | University of Jena | Phase 3 | 2005-12-01 | Rhinosinusitis disorders are often associated with Cystic Fibrosis. They can restrict quality of life enormously and give cause to repeated ENT surgery. The basic defect in CF is a dysfunction of Chloride channels in exocrine glands, leading to retention of secretions and consecutive chronic inflammation with bacterial superinfections. The prospective placebo controlled cross-over study aims at the evaluation of the efficacy of a nasally inhalation of Pulmozyme with respect to mucus retention and resulting inflammation. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for dornase alfa
Condition Name
Clinical Trial Locations for dornase alfa
Trials by Country
Clinical Trial Progress for dornase alfa
Clinical Trial Phase
Clinical Trial Sponsors for dornase alfa
Sponsor Name
